XNCR Xencor Inc.

34.33
-1.68  -5%
Previous Close 36.01
Open 36.13
Price To Book 3.19
Market Cap 1,947,237,835
Shares 56,721,172
Volume 599,778
Short Ratio
Av. Daily Volume 363,649
Stock charts supplied by TradingView

NewsSee all news

  1. Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has

  2. Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the

  3. Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the

  4. Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting

    -- Live webcast to review initial clinical data at 8:30 p.m. EST tonight -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer,

  5. Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data released October 5, 2018. Primary endpoint not met.
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 3 trial to be initiated - partner required.
XmAb5871
IgG4-Related Disease (IgG4-RD)
Phase 1 trial placed on partial clinical hold - February 20, 2019.
XmAb14045
Acute Myeloid Leukemia (AML)
Phase 1 initial data at ASH December 9, 2019 - generally well tolerated.
XmAb13676
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 initial data due 1H 2020.
XmAb18087
Neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)
Phase 1 initiation of dosing announced May 6, 2019.
XmAb23104-01 (DUET-3)
Solid tumors
Phase 1 commencement of dosing announced June 3, 2019.
XmAb22841
Solid tumors
Phase 1 initial data due 1H 2020.
XmAb20717 (DUET-2)
Solid tumors

Latest News

  1. Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has

  2. Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the

  3. Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the

  4. Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting

    -- Live webcast to review initial clinical data at 8:30 p.m. EST tonight -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer,

  5. Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that

  6. Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that

  7. Xencor Reports Third Quarter 2019 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune

  8. Xencor to Present at the 2019 Cantor Global Healthcare Conference

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that

  9. Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the